Home About us Contact
|
Home About us Contact | ||
|
|
||
Plasma Fraction (plasma + fraction)
Selected AbstractsDistribution of carbon-14 labeled C60 ([14C]C60) in the pregnant and in the lactating dam and the effect of C60 exposure on the biochemical profile of urineJOURNAL OF APPLIED TOXICOLOGY, Issue 4 2010Susan C. J. Sumner Abstract This study was conducted to determine the distribution of [14C]C60 in the pregnant rat and fetuses, and in the lactating rat and offspring. Pregnant rats were dosed on gestation day (gd) 15 and lactating rats were dosed on postnatal day (pnd) 8 via tail vein injection with a suspension of ,0.3,mg [14C]C60,kg,1 body weight prepared in polyvinylpyrrolidone (PVP), or with PVP alone. Tissues were collected at 24 and 48 h after dosing. The largest portion of the administered dose was detected in the liver (,43%, pregnant dam; ,35%, lactating dam) and lung (,25%, lactating dam). Radioactivity (,6%) was distributed to the reproductive tract, placenta and fetuses of the pregnant dam. Lactating rats had radioactivity distributed to the milk (3140,dpm,g,1 tissue, 24,h; 1620,dpm,g,1 tissue, 48,h), and to the pups' GI tract (2.8%, 24,h; 4.4% 48,h) and liver (<1%). Blood radioactivity was significant at 24,h (14,19%) and at 48,h (7%) after dosing; largely accounted for in the plasma fraction. Less that 4% of the dose was recovered in the maternal spleen, heart, brain, urine or feces. Metabolomics analysis of urine indicated that dams exposed to [14C]C60 had decreased metabolites derived from the Krebs cycle and increased metabolites derived from the urea cycle or glycolysis, as well as alterations in the levels of some sulfur-containing amino acids and purine/pyrimidine metabolites. This study demonstrated that [14C]C60 crosses the placenta and is transmitted to offspring via the dam's milk and subsequently systemically absorbed. Copyright © 2009 John Wiley & Sons, Ltd. [source] Prevalence of persistent and latent viruses in untreated patients infected with HIV-1 from Ghana, West AfricaJOURNAL OF MEDICAL VIROLOGY, Issue 11 2009Lara Isobel Compston Abstract Only limited epidemiological data, pertaining to the prevalence of common persistent viruses has been reported in Ghana. This study was conducted to determine the prevalence of persistent viruses in individuals with untreated HIV-1 infection and uninfected blood donors. Paired plasma and cellular samples from HIV-negative blood donors, asymptomatic HIV and symptomatic/AIDS cohorts were screened by multiplex PCR then qPCR for parvovirus B19 (B19V), hepatitis B virus (HBV), GB virus-C (GBV-C), cytomegalovirus (CMV), Epstein,Barr virus (EBV), human herpesvirus-8 (HHV-8) and varicella-zoster virus (VZV). IgG antibodies specific to each target virus were tested to determine exposure rates. No evidence of viraemia was found for B19V and VZV in any group. Prevalence of GBV-C plasma viraemia was significantly higher in asymptomatic and symptomatic HIV infection (16.7%) and (16.2%) than in blood donors (4%) P,<,0.005. Occult HBV infection was significantly more frequent in symptomatic HIV infection (10.9%) compared to asymptomatic HIV (3.6%) and blood donors (1.6%) P,<,0.005. Although there was a high background of EBV viraemia in cellular fractions of blood donors (8.3%), it was significantly higher in asymptomatic (44.6%) and symptomatic HIV (14.6%) P,<,0.0001. For CMV, the significantly increased prevalence of viraemia was only observed in the plasma fraction of the symptomatic HIV-1/AIDS patients (7.6%) compared to asymptomatic individuals (1.8%) and blood donors (0.8%) P,,,0.001. The background seroprevalence in blood donors was high for B19V (,64%), HBV (,70%), CMV and EBV (,90%) and was significantly increased in HIV infections for HBV, CMV, VZV (symptomatic HIV), and HHV-8 (asymptomatic and symptomatic HIV). J. Med. Virol. 81:1860,1868, 2009. © 2009 Wiley-Liss, Inc. [source] Biomarkers of Mn exposure in humansAMERICAN JOURNAL OF INDUSTRIAL MEDICINE, Issue 11 2007Donald Smith PhD Abstract Background Studies have reported associations between manganese (Mn) exposures and Mn levels in blood and urine, though the suitability of these biological measures as biomarkers of exposure is not well known. Methods We evaluated whether whole blood, plasma, and urine Mn levels reflect exposures in occupationally exposed humans. Results In active ferroalloy workers, blood Mn was associated with total air Mn levels in subjects currently exposed to low (median,=,0.42 ,g/m3, P,=,0.009) and moderate (median,=,4.2 ,g/m3, P,=,0.007) air Mn levels, but not in workers exposed to the highest Mn levels (median,=,292 ,g/m3, P,=,0.31). In bridge welders blood Mn (P,<,0.01), but not plasma or urine Mn was significantly associated with their cumulative respiratory exposure index. In welders, ,6% (range ,3,9%) of whole blood Mn was contained in the plasma fraction, though there was no association between whole blood and plasma Mn levels (Pearson's R,=,0.258, P,=,0.12). In contrast, in fresh whole blood samples spiked with Mn ex vivo ,80% or more of added Mn partitioned in the plasma, while only ,20% or less partitioned in the cellular fraction. Conclusions These data suggest a complex and limited relationship between exposure and blood Mn levels that may depend upon exposure attributes and the latency of blood sampling relative to exposure; plasma and urine Mn appear to be of little utility as exposure biomarkers. This underscores the need to fully characterize and validate these or other biomarkers for use in constructing appropriate exposure metrics and determining exposure,effect relationships. Am. J. Ind. Med. 50:801,811, 2007. © 2007 Wiley-Liss, Inc. [source] A global view on prophylaxis: possibilities and consequencesHAEMOPHILIA, Issue 2003A. D. Shapiro Summary., Prophylactic infusion therapy, both primary and secondary, has proven of great benefit to patients with haemophilia, specifically those with severe disease or bleeding episodes and patterns that have lead to development of arthropathy. At this time, optimal outcome in patients with severe haemophilia has been proven achievable with primary prophylaxis initiated at an early age in a regimen of three times weekly or every other day for patients with factor VIII deficiency, and twice weekly for those with factor IX deficiency. Despite the demonstrated benefit of primary prophylaxis, this treatment regimen has not been uniformly adopted into clinical practice even in developed countries. In developing countries, where issues of allocation of precious health care resources are of paramount importance, access to adequate treatment for persons with haemophilia on a programme of on-demand therapy is not commonly available; the cost of primary prophylaxis, even with intermediate purity plasma-derived factor concentrates or plasma fractions such as cryoprecipitate, renders this treatment the exception rather than the rule. [source] | ||||||||||